T he development of antiarrhythmic therapies is a costly endeavor. Computational models have increasingly been included in the drug development pipeline as a method to screen potentially proarrhythmic compounds and provide a critical link between protein scale perturbations (e.g., ion channel mutations) and tissue scale behavior (e.g., arrhythmia episodes). As experiments have more clearly elucidated ion channel dynamics, computational models too need to incorporate more detailed representations of channel responses.
This framework was also critical to more accurately model drugs that target ion channels. Simply put, a drug may only access its binding site when the channel is in specific states; therefore, representing state-specific binding rates is critical. Moreno et al. (1) previously applied such an in silico approach to explain the paradoxically proarrhythmic response of the sodium channel blocker flecainide.
Sodium channel Markov models have been expanded to account for several variants of gain-offunction mutations in the SCN5A gene, encoding the alpha subunit of the Na v 1.5 channel, that are associated with long QT type 3 syndrome (LQT3). Although the phenotypes associated with these variants are similar, a late sodium current which prolongs the action potential duration (APD), the mechanism by which the late current manifest differs among variants. This suggests that a "one size fits all" therapy to treat LQT3 may be problematic. How to Boost Efficacy of a Sodium Channel Blocker pools is particularly critical in LQT3, as the present authors recently showed that Na v 1.5 preferential localization at the intercalated disk can reduce the late sodium current and suppress EAD formation (5) .
Despite these additional qualifications, the study 
